Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness

Science Translational Medicine

Volumn 2, Issue 21, 2010, Pages

  Amado, Defne ^a   Mingozzi, Federico ^b   Hui, Daniel ^b   Bennicelli, Jeannette L ^a   Wei, Zhangyong ^a   Chen, Yifeng ^b,c   Bote, Erin ^d   Grant, Rebecca L ^d   Golden, Jeffrey A ^b,d   Narfstrom, Kristina ^e   Syed, Nasreen A ^f   Orlin, Stephen E ^a   High, Katherine A ^b,c   Maguire, Albert M ^a,b   Bennett, Jean ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GAMMA INTERFERON; IMMUNOGLOBULIN ANTIBODY; INTERLEUKIN 10; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; RETINAL PIGMENT EPITHELIUM PROTEIN; UNCLASSIFIED DRUG; VISUAL PROTEINS AND PIGMENTS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STABILITY; ENDOPHTHALMITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE EXAMINATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; LEBER CONGENITAL AMAUROSIS; MOLECULAR WEIGHT; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RHESUS MONKEY; SEROTYPE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS RECOMBINANT; VISION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTERIOR CHAMBER; ANTIBODIES, NEUTRALIZING; BLINDNESS; CAPSID; CARRIER PROTEINS; DEPENDOVIRUS; DOGS; DRUG ADMINISTRATION ROUTES; EYE PROTEINS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POSTMORTEM CHANGES; PRIMATES; RETINA; TITRIMETRY; TREATMENT OUTCOME;

EID: 77952983302     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000659     Document Type: Article

References (37)

1. -/- mice and humans with Leber congenital amaurosis. Invest. Ophthalmol. Vis. Sci. 45, 1259-1271 (2004).
2. B. Lorenz, P. Gyürüs, M. Preising, D. Bremser, S. Gu, M. Andrassi, C. Gerth, A. Gal, Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest. Ophthalmol. Vis. Sci. 41, 2735-2742 (2000).
3. F. Simonelli, C. Ziviello, F. Testa, S. Rossi, E. Fazzi, P. E. Bianchi, M. Fossarello, S. Signorini, C. Bertone, S. Galantuomo, F. Brancati, E. M. Valente, A. Ciccodicola, E. Rinaldi, A. Auricchio, S. Banfi, Clinical and molecular genetics of Leber's congenital amaurosis: A multicenter study of Italian patients. Invest. Ophthalmol. Vis. Sci. 48, 4284-4290 (2007).
4. I. Perrault, J. M. Rozet, S. Gerber, I. Ghazi, C. Leowski, D. Ducroq, E. Souied, J. L. Dufier, A. Munnich, J. Kaplan, Leber congenital amaurosis. Mol. Genet. Metab. 68, 200-208 (1999).
5. A. I. den Hollander, R. Roepman, R. K. Koenekoop, F. P. Cremers, Leber congenital amaurosis: Genes, proteins and disease mechanisms. Prog. Retin. Eye Res. 27, 391-419 (2008).
6. G. Moiseyev, Y. Chen, Y. Takahashi, B. X. Wu, J. X. Ma, RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc. Natl. Acad. Sci. U.S.A. 102, 12413-12418 (2005).
7. M. Jin, S. Li, W. N. Moghrabi, H. Sun, G. H. Travis, Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell 122, 449-459 (2005).
8. T. M. Redmond, S. Yu, E. Lee, D. Bok, D. Hamasaki, N. Chen, P. Goletz, J. X. Ma, R. K. Crouch, K. Pfeifer, Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat. Genet. 20, 344-351 (1998).
9. T. M. Redmond, E. Poliakov, S. Yu, J. Y. Tsai, Z. Lu, S. Gentleman, Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc. Natl. Acad. Sci. U.S.A. 102, 13658-13663 (2005).
10. A. M. Maguire, F. Simonelli, E. A. Pierce, E. N. Pugh Jr., F. Mingozzi, J. Bennicelli, S. Banfi, K. A. Marshall, F. Testa, E. M. Surace, S. Rossi, A. Lyubarsky, V. R. Arruda, B. Konkle, E. Stone, J. Sun, J. Jacobs, L. Dell'Osso, R. Hertle, J. X. Ma, T.M. Redmond, X. Zhu, B. Hauck, O. Zelenaia, K. S. Shindler, M. G. Maguire, J. F.Wright, N. J. Volpe, J.W. McDonnell, A. Auricchio, K. A. High, J. Bennett, Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248 (2008).
11. J. W. Bainbridge, A. J. Smith, S. S. Barker, S. Robbie, R. Henderson, K. Balaggan, A. Viswanathan, G. E. Holder, A. Stockman, N. Tyler, S. Petersen-Jones, S. S. Bhattacharya, A. J. Thrasher, F. W. Fitzke, B. J. Carter, G. S. Rubin, A. T. Moore, R. R. Ali, Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239 (2008).
12. A. V. Cideciyan, T. S. Aleman, S. L. Boye, S. B. Schwartz, S. Kaushal, A. J. Roman, J. J. Pang, A. Sumaroka, E. A. Windsor, J. M. Wilson, T. R. Flotte, G. A. Fishman, E. Heon, E. M. Stone, B. J. Byrne, S. G. Jacobson, W. W. Hauswirth, Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. U.S.A. 105, 15112-15117 (2008).
13. W. W. Hauswirth, T. S. Aleman, S. Kaushal, A. V. Cideciyan, S. B. Schwartz, L. Wang, T. J. Conlon, S. L. Boye, T. R. Flotte, B. J. Byrne, S. G. Jacobson, Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum. Gene Ther. 19, 979-990 (2008).
14. A. V. Cideciyan, W. W. Hauswirth, T. S. Aleman, S. Kaushal, S. B. Schwartz, S. L. Boye, E. A. Windsor, T. J. Conlon, A. Sumaroka, J. J. Pang, A. J. Roman, B. J. Byrne, S. G. Jacobson, Human RPE65 gene therapy for Leber congenital amaurosis: Persistence of early visual improvements and safety at 1 year. Hum. Gene Ther. 20, 999-1004 (2009).
15. A. M. Maguire, K. A. High, A. Auricchio, J. F. Wright, E. A. Pierce, F. Testa, F. Mingozzi, J. L. Bennicelli, G. S. Ying, S. Rossi, A. Fulton, K. A.Marshall, S. Banfi, D. C. Chung, J. I.Morgan, B. Hauck, O. Zelenaia, X. Zhu, L. Raffini, F. Coppieters, E. De Baere, K. S. Shindler, N. J. Volpe, E. M. Surace, C. Acerra, A. Lyubarsky, T. M. Redmond, E. Stone, J. Sun, J. W. McDonnell, B. P. Leroy, F. Simonelli, J. Bennett, Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374, 1597-1605 (2009).
16. F. Simonelli, A. M. Maguire, F. Testa, E. A. Pierce, F. Mingozzi, J. L. Bennicelli, S. Rossi, K. Marshall, S. Banfi, E.M. Surace, J. Sun, T.M. Redmond, X. Zhu, K. S. Shindler, G. S. Ying, C. Ziviello, C. Acerra, J. F. Wright, J. W. McDonnell, K. A. High, J. Bennett, A. Auricchio, Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther., 10.1038/mt.2009.277 (2009).
17. K. Narfström, A. Wrigstad, S. E. Nilsson, The Briard dog: A new animal model of congenital stationary night blindness. Brit. J. Ophthalmol. 73, 750-756 (1989).
18. G. D. Aguirre, V. Baldwin, S. Pearce-Kelling, K. Narfström, K. Ray, G. M. Acland, Congenital stationary night blindness in the dog: Common mutation in the RPE65 gene indicates founder effect. Mol. Vis. 4, 23 (1998).
19. N. Muzyczka, K. Berns, in Fields Virology, D. Knipe, P. Howley, Eds. (Lippincott Williams & Wilkins, Philadelphia, vol. 2, 2001), pp. 2327-2359.
20. J. Bennicelli, J. F. Wright, A. Komaromy, J. B. Jacobs, B. Hauck, O. Zelenaia, F. Mingozzi, D. Hui, D. Chung, T. S. Rex, Z. Wei, G. Qu, S. Zhou, C. Zeiss, V. R. Arruda, G. M. Acland, L. F. Dell'Osso, K. A. High, A. M. Maguire, J. Bennett, Reversal of blindness in animal models of Leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol. Ther. 16, 458-465 (2008).
21. G. M. Acland, G. D. Aguirre, J. Ray, Q. Zhang, T. S. Aleman, A. V. Cideciyan, S. E. Pearce-Kelling, V. Anand, Y. Zeng, A. M. Maguire, S. G. Jacobson, W. W. Hauswirth, J. Bennett, Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92-95 (2001).
22. G. M. Acland, G. D. Aguirre, J. Bennett, T. S. Aleman, A. V. Cideciyan, J. Bennicelli, N. S. Dejneka, S. E. Pearce-Kelling, A. M. Maguire, K. Palczewski, W. W. Hauswirth, S. G. Jacobson, Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol. Ther. 12, 1072-1082 (2005).
23. J. B. Jacobs, L. F. Dell'Osso, R. W. Hertle, G. M. Acland, J. Bennett, Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: Implications for the ocular motor system. Invest. Ophthalmol. Vis. Sci. 47, 2865-2875 (2006).
24. J. B. Jacobs, L. F. Dell'Osso, Z. I. Wang, G. M. Acland, J. Bennett, Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA. Invest. Ophthalmol. Vis. Sci. 50, 4685-4692 (2009).
25. V. Anand, N. Chirmule, M. Fersh, A. M. Maguire, J. Bennett, Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum. Gene Ther. 11, 449-457 (2000).
26. J. Bennett, V. Anand, G. M. Acland, A. M. Maguire, Cross-species comparison of in vivo reporter gene expression after recombinant adeno-associated virus-mediated retinal transduction. Methods Enzymol. 316, 777-789 (2000).
27. Q. Li, R. Miller, P. Y. Han, J. Pang, A. Dinculescu, V. Chiodo, W. W. Hauswirth, Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol. Vis. 14, 1760-1769 (2008).
28. A. Liekfeld, F. Schweig, C. Jaeckel, K. D. Wernecke, C. Hartmann, U. Pleyer, Intraocular antibody production in intraocular inflammation. Graefes Arch. Clin. Exp. Ophthalmol. 238, 222-227 (2000).
29. P. Y. Robert, A. Liekfeld, S. Metzner, S. Ranger-Rogez, J. P. Adenis, F. Denis, C. Hartmann, U. Pleyer, Specific antibody production in herpes keratitis: Intraocular inflammation and corneal neovascularisation as predicting factors. Graefes Arch. Clin. Exp. Ophthalmol. 244, 210-215 (2006).
30. L. de Visser, A. Rothova, J. H. de Boer, A. M. van Loon, F. T. Kerkhoff, M. R. Canninga-van Dijk, A. Y. Weersink, J. D. de Groot-Mijnes, Diagnosis of ocular toxocariasis by establishing intraocular antibody production. Am. J. Ophthalmol. 145, 369-374 (2008).
31. S. E. Barker, C. A. Broderick, S. J. Robbie, Y. Duran, M. Natkunarajah, P. Buch, K. S. Balaggan, R. E. MacLaren, J. W. Bainbridge, A. J. Smith, R. R. Ali, Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. J. Gene Med. 11, 486-497 (2009).
32. N. Chirmule, K. Propert, S. Magosin, Y. Qian, R. Qian, J. Wilson, Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574-1583 (1999).
33. N. R. Blacklow, M. D. Hoggan, A. Z. Kapikian, J. B. Austin, W. P. Rowe, Epidemiology of adenovirusassociated virus infection in a nursery population. Am. J. Epidemiol. 88, 368-378 (1968).
34. C. L. Chen, R. L. Jensen, B. C. Schnepp, M. J. Connell, R. Shell, T. J. Sferra, J. S. Bartlett, K. R. Clark, P. R. Johnson, Molecular characterization of adeno-associated viruses infecting children. J. Virol. 79, 14781-14792 (2005).
35. C. S. Manno, G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, M. Dake, R. Kaye, M. Razavi, A. Zajko, J. Zehnder, P. K. Rustagi, H. Nakai, A. Chew, D. Leonard, J. F. Wright, R. R. Lessard, J. M. Sommer, M. Tigges, D. Sabatino, A. Luk, H. Jiang, F. Mingozzi, L. Couto, H. C. Ertl, K. A. High, M. A. Kay, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347 (2006).
36. F. Mingozzi, N. C. Hasbrouck, E. Basner-Tschakarjan, S. A. Edmonson, D. J. Hui, D. E. Sabatino, S. Zhou, J. F. Wright, H. Jiang, G. F. Pierce, V. R. Arruda, K. A. High, Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110, 2334-2341 (2007).
37. + T-cell responses to adenoassociated virus capsid in humans. Nat. Med. 13, 419-422 (2007).